Transgene . (NASDAQ:TRGNY)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Transgene . Charts. Click Here for more Transgene . Charts.](/p.php?pid=staticchart&s=N%5ETRGNY&p=8&t=15)
Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer
Vaccine at ASCO's 2005 Annual Meeting
STRASBOURG, France, April 5 /PRNewswire-FirstCall/ -- Transgene (Nasdaq:
TRGNY; Eurolist Paris: FR0005175080) announced today that data from the
MVA-MUC1-IL2 cancer vaccine Phase II trials in non-small cell lung and prostate
cancers has been accepted for presentation at the 2005 Annual Meeting of ASCO
(American Society of Clinical Oncology). The meeting will take place in
Orlando, Florida, May 13-17, 2005.
1. Poster presentation: "A Phase II study evaluating the clinical
efficacy of MVA-MUC1-IL2 (TG4010) in association with chemotherapy in
patients with Non Small Cell Lung Cancer". Presented by Prof. Thierry
Velu, Academic Erasme Hospital, Brussels, Belgium.
2. Oral presentation in the genito-urinary scientific program: "MVA-MUC1-
IL2 vaccine immunotherapy (TG4010) in patients with prostate cancer
with biochemical failure". Presented by Dr. Robert Dreicer, Cleveland
Clinic Foundation, Cleveland, Ohio.
"We are very pleased that two abstracts describing clinical results with our
cancer vaccine MVA-MUC1-IL2 have been selected for presentation at this year's
ASCO meeting," said Dr. Patrick Squiban, MD, VP, Medical and Regulatory Affairs
of Transgene. "It will be an opportunity to communicate updated, additional
data beyond the promising interim results that we have released up to now."
About Transgene:
Transgene, based in Strasbourg, France, is a biopharmaceutical company
dedicated to the discovery and development of therapeutic vaccines and
immunotherapy products for the treatment of cancer and infectious diseases.
Transgene has a broad portfolio of products in clinical development.
This press release contains a forward-looking statement regarding the potential
efficacy of one of Transgene's cancer vaccine candidates. The results of
clinical testing to date are preliminary and based upon a small number of
patients. As is the case with all biopharmaceutical products under
development, results from future studies with more data may show less
favourable outcomes.
DATASOURCE: Transgene
CONTACT: Patrick Squiban, MD, VP, Medical and Regulartory Affairs,
Transgene, +33-3-88-27-91-73; Michael Long, Cohn & Wolfe, +1-415-365-8523;
Tiphaine Hecketsweiler of Image 7, +33-1-53-70-74-70, both for Transgene
Web site: http://www.transgene.fr/